Moreover, the pharmacological blockade of AT-II activity by the angiotensin-converting enzyme inhibitor (ACE-I) or AT-II receptor type 1 (AT1R) blocker (ARB) suppresses the pro-fibrotic properties of HSCs and attenuates liver fibrosis in rodents [14,15,16]. This evidence concerns the gene AGTR1 and Hepatic fibrosis.